Refine
Year of publication
Has Fulltext
- yes (903)
Is part of the Bibliography
- no (903)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (10)
- LHC (7)
- Heavy-ion collision (5)
- Jets (5)
- Collective Flow (4)
- Quark-Gluon Plasma (4)
- (surface) partial differential equations (3)
- ALICE (3)
- Finite Volumes (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- computational virology (3)
- massively parallel multigrid solvers (3)
- realistic geometries (3)
- viral dynamics (3)
- 3D spatio-temporal resolved mathematical models (2)
- ALICE experiment (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Quark Gluon Plasma (2)
- Quarkonium (2)
- hepatitis C virus (HCV) (2)
- mathematical models of viral RNA cycle (2)
- pp collisions (2)
- within-host viral modelling (2)
- 3D spatiotemporal resolved mathematical models (1)
- 900 GeV (1)
- ALICE detector (1)
- ARDS (1)
- Analysis and statistical methods (1)
- Anti-nuclei (1)
- Beauty production (1)
- Boosted Jets (1)
- COVID-19 (1)
- CVID (1)
- Calorimeters (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Critical care (1)
- Data processing methods (1)
- Double-blind placebo-controlled trial (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exercise challenge (1)
- Exercise-induced asthma (1)
- Exhaled nitric oxide (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Forced expiratory volume in 1 s (1)
- Genetic testing (1)
- German PID-NET registry (1)
- Guided waves (1)
- H1N1 (1)
- HBT (1)
- HSCT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy-Ion Collision (1)
- Heavy-ion collisions (1)
- Hemagglutination inhibition assay (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Liver cirrhosis (1)
- Longchain polyunsaturated fatty acids (1)
- Material budget (1)
- Mid-rapidity (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Nuclear modification factor (1)
- Outcome (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Pb–Pb collisions (1)
- Performance of High Energy Physics Detectors (1)
- Portal hypertension (1)
- Primary prophylaxis (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- QCD (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Relativistic heavy-ion collisions (1)
- Single electrons (1)
- Single muons (1)
- Spontaneous bacterial peritonitis (1)
- TR (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- bevacizumab (1)
- composite structures (1)
- dE/dx (1)
- detector (1)
- elderly (1)
- experimental results (1)
- first-line chemotherapy (1)
- heavy ion experiments (1)
- hepatitis C virus (1)
- metastatic colorectal cancer (1)
- parameter estimation (1)
- population dynamics (1)
- primary immunodeficiency (PID) (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- scanning laser Doppler vibrometry (1)
- signal processing (1)
- spectra (1)
- structural health monitoring (1)
- within-host viral modeling (1)
- √sN N = 2.76 TeV (1)
Institute
Ultrasonic guided waves have been used successfully in structural health monitoring systems to detect damage in isotropic and composite materials with simple and complex geometry. A limitation of current research is given by a lack of freely available benchmark measurements to comparatively evaluate existing methods. This article introduces the extendable online platform Open Guided Waves (http://www.open-guided-waves.de) where high-quality and well-documented datasets for guided wave-based inspections are provided. In this article, we describe quasi-isotropic carbon-fiber-reinforced polymer plates with embedded piezoelectric transducers as a first benchmark structure. Intentionally, this is a structure of medium complexity to enable many researchers to apply their methods. In a first step, ultrasound and X-ray measurements were acquired to verify pristine conditions. Next, mechanical testing was done to determine the stiffness tensor and sample density based on standard test procedures. Guided wave measurements were divided into two parts: first, acoustic wave fields were acquired for a broad range of frequencies by three-dimensional scanning laser Doppler vibrometry. Second, structural health monitoring measurements in the carbon-fiber-reinforced polymer plate were collected at constant temperature using a distributed transducer network and a surface-mounted reversible defect model. Initial results serving as validation are presented and discussed.
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after 1 or 2 doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients (ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer of ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4-fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received 1 dose and 11 of these patients 2 doses of the vaccine. The rate of seroconversion was 41.2% (95% confidence interval [CI] 18.4-67.1) after the first and 81.8% (95% CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after 1 dose of the vaccine were more likely to receive any immunosuppressive agent (P = .003), but time elapsed after or type of HSCT, age, sex, or chronic graft-versus-host disease was not different when compared to patients with seroconversion. In patients with hematologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1 influenza A vaccine was poor, but increased after a second dose.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.